Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFutura Medical Regulatory News (FUM)

Share Price Information for Futura Medical (FUM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.25
Bid: 39.35
Ask: 39.50
Change: 2.10 (5.65%)
Spread: 0.15 (0.381%)
Open: 37.95
High: 40.80
Low: 37.95
Prev. Close: 37.15
FUM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Licenses CSD500 to Church & Dwight

2 Apr 2013 07:00

RNS Number : 2832B
Futura Medical PLC
02 April 2013
 



For immediate release

2 April 2013

 

 

Futura Medical PLC

("Futura" or the "Company")

 

Futura licenses CSD500 to Church & Dwight

 

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, announces that it has signed a licensing deal with Church & Dwight Co Inc, the major US consumer products group whose brands include Trojan® condoms, for the marketing and distribution of CSD500, Futura's novel condom.

 

Trojan® is the number one condom brand in North America and the world's second biggest condom brand by product sales.

 

Under the terms of the agreement, Church & Dwight will hold the rights to manufacture, market and distribute CSD500 in North America and in a number of key European territories.

 

The financial details of the agreement are not being disclosed although Futura will receive an upfront payment and royalties on all product sales along with certain minimum performance guarantees.

 

Adrian Huns, Church & Dwight's President of International Consumer Products, commented: "CSD500 is a genuinely novel condom that marks a major breakthrough in condom technology. We look forward to working with Futura on the successful completion of the required approvals necessary ahead of the launch in Europe and North America of a completely new type of condom from a highly trusted brand."

 

James Barder, Futura's Chief Executive, commented: "We are delighted to sign this pivotal agreement with Church & Dwight for the marketing of CSD500 as a Trojan®-branded condom in North America and in key territories in Europe. Trojan® is one of the world's biggest condom brands and the number one brand in North America."

 

"The agreement is in line with the Board's preferred strategy of licensing CSD500 on a geographic basis to condom distributors that hold leading positions in their regions. We continue to negotiate CSD500 rights for other major territories and believe that this strategy will create optimal value for shareholders."

 

 

For further information:

 

Futura Medical plc

+ 44 (0) 1483 685 670

James Barder, Chief Executive

Mail to: James.Barder@futuramedical.com

www.futuramedical.com

Nomura Code Securities Limited

+ 44 (0) 20 7776 1200

Phil Walker / Giles Balleny

Buchanan

+ 44 (0) 20 7466 5000

Mark Court / Fiona Henson / Sophie Cowles

 

 

Notes to editors:

 

About Futura Medical plc

 

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

 

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

 

www.futuramedical.com 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCNKBDQPBKKNQK
Date   Source Headline
1st Apr 20207:00 amRNSFull Year Results for the year ended 31 Dec 2019
16th Mar 20207:00 amRNSNotice of Results
5th Mar 20207:00 amRNSFutura to Update on MED3000 at Investor Seminar
27th Feb 20209:37 amRNSHolding(s) in Company
17th Feb 202012:53 pmRNSHolding(s) in Company
13th Feb 20207:00 amRNSUpdate on positive EU regulatory discussions
30th Jan 20207:00 amRNSTotal Voting Rights
22nd Jan 20202:33 pmRNSRemuneration of NED and Total Voting Rights
21st Jan 20202:17 pmRNSHolding(s) in Company
21st Jan 20201:44 pmRNSHolding(s) in Company
17th Jan 202012:12 pmRNSGM Statement
7th Jan 202011:05 amRNSSecond Price Monitoring Extn
7th Jan 202011:00 amRNSPrice Monitoring Extension
27th Dec 20197:00 amRNSPosting of Circular and Notice of General Meeting
23rd Dec 20197:00 amRNSResult of Fundraising
20th Dec 20194:40 pmRNSSecond Price Monitoring Extn
20th Dec 20194:35 pmRNSPrice Monitoring Extension
20th Dec 20194:31 pmRNSPrimaryBid Offer
20th Dec 20194:30 pmRNSCorporate Update & Proposed Fundraising
17th Dec 20194:41 pmRNSSecond Price Monitoring Extn
17th Dec 20194:35 pmRNSPrice Monitoring Extension
17th Dec 201911:05 amRNSSecond Price Monitoring Extn
17th Dec 201911:00 amRNSPrice Monitoring Extension
16th Dec 20199:05 amRNSSecond Price Monitoring Extn
16th Dec 20199:00 amRNSPrice Monitoring Extension
13th Dec 20199:05 amRNSSecond Price Monitoring Extn
13th Dec 20199:00 amRNSPrice Monitoring Extension
10th Dec 20194:40 pmRNSSecond Price Monitoring Extn
10th Dec 20194:35 pmRNSPrice Monitoring Extension
10th Dec 201911:05 amRNSSecond Price Monitoring Extn
10th Dec 201911:00 amRNSPrice Monitoring Extension
10th Dec 20199:05 amRNSSecond Price Monitoring Extn
10th Dec 20199:00 amRNSPrice Monitoring Extension
10th Dec 20197:00 amRNSTop Line Results from MED2005 Phase 3 study
6th Dec 20194:10 pmRNSBlock Listing Six Monthly Return
22nd Nov 201911:48 amRNSHolding(s) in Company
20th Nov 20194:05 pmRNSHolding(s) in Company
20th Nov 20194:04 pmRNSHolding(s) in Company
14th Nov 20197:00 amRNSPublishes Fireside Chat with Prof Wayne Hellstrom
11th Nov 201912:44 pmRNSHolding(s) in Company
29th Oct 201910:03 amRNSHolding(s) in Company
28th Oct 20194:12 pmRNSMED2005 Safety and Efficacy Data Reported at SMSNA
23rd Oct 201912:46 pmRNSChange of Auditor
21st Oct 20197:00 amRNSFinal Dosing of Last Patient in MED2005 Ph3 study
15th Oct 20195:44 pmRNSFutura Medical to Present Data on MED2005 at SMSNA
15th Oct 20195:42 pmRNSDirector / PCA Shareholding
18th Sep 20195:42 pmRNSDirector/PDMR Shareholding
16th Sep 201910:11 amRNSHolding(s) in Company
13th Sep 20194:40 pmRNSSecond Price Monitoring Extn
13th Sep 20194:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.